RxDoctor Payments Data

Philip Jessen, APRN

Nurse Practitioner · Fort Walton Beach, FLNPI 1871977173

Payments from drug & device makers

$3,665in general payments, 2019–2025

Across 214 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$583
  • Amgen$445
  • Novo Nordisk$370
  • Dexcom, Inc.$359
  • Johnson & Johnson$334
  • Lilly USA, LLC$323
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,665100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,665 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$220,496
Medicare patients
764
Services billed
4,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$212,210
JardianceEmpagliflozin135$183,922
MounjaroTirzepatide63$100,507
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$66,898
EliquisApixaban51$49,478
FarxigaDapagliflozin Propanediol34$47,237
RybelsusSemaglutide25$44,043
TrulicityDulaglutide20$39,625
EntrestoSacubitril/Valsartan18$24,698
XareltoRivaroxaban14$21,130
AptiomEslicarbazepine Acetate13$15,072
MyrbetriqMirabegron25$13,720
Albuterol Sulfate HfaAlbuterol Sulfate91$4,175
Celecoxib42$3,808
Lidocaine16$3,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$370$256,254177 claims
Boehringer IngelheimJardiance$174$183,922135 claims
Lilly USA, LLCMounjaro, Trulicity$323$140,13383 claims
GSKTrelegy Ellipta$583$66,89847 claims
PfizerEliquis$281$49,47851 claims
AstraZenecaFarxiga$280$47,23734 claims
NovartisEntresto$24$24,69818 claims
Johnson & JohnsonXarelto$334$21,13014 claims
Astellas Pharma US IncMyrbetriq$115$13,72025 claims
AbbVieSynthroid$14$2,03030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Fort Walton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →